Tamika Mitchell

Baylor College of Medicine — United States

Medicine · Health Sciences

11h-index822citations48works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(18), Monoclonal and Polyclonal Antibodies Research(18), Advanced Breast Cancer Therapies(15), Advanced Biosensing Techniques and Applications(9), Microtubule and mitosis dynamics(8)

Publications48 total

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer
Cell Reports·2023· 16 citedOpen Access
Data from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Supplementary information from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Table from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Data from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023· 1 citedOpen Access
Supplementary Figures from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Figures 1-15 from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Supplementary Tables from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Tables from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Auxiliary Supplementary File from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Auxiliary Supplementary File from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Supplementary Methods from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Data from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Figures from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Supplementary information from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Methods from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Supplementary Table from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Data from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
2023Open Access
Supplementary Figures 1-15 from Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
2023Open Access
Abstract 1077: Acquired neratinib resistance is associated with acquisition of <i>HER2</i> and <i>PIK3CA</i> mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models
Cancer Research·2021· 1 cited
page 1 of 3Next →

Frequent Co-authors

Rachel Schiff(46), Martin J. Shea(41), Jamunarani Veeraraghavan(32), Lanfang Qin(31), Susan G. Hilsenbeck(30), Sarmistha Nanda(28), Mothaffar F. Rimawi(23), Carmine De Angelis(21), Vidyalakshmi Sethunath(21), Carolina Gutiérrez(18), Agostina Nardone(16), C. Kent Osborne(14), Chandandeep Nagi(13), Chad A. Shaw(13), Huizhong Hu(12), C. Kent Osborne(12), Gary C. Chamness(11), Chia-Chia Liu(11), Xixi Cao(11), Suet Kee Loo(11)